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Background: The null genotype of GSTM1 have been implicated in gastric cancer risk, but numerous individual
studies showed mixed, or even conflicting results. Thus, a meta-analysis was performed.
Results: We identified 54 individual studies involving 9,322 cases and 15,118 controls through computer-based
searches of PubMed, Embase, and Cochrane Library. It was found that the null genotype of GSTM1 was associated
with an increased gastric cancer risk (OR = 1.207, 95% CI: 1.106-1.317, P < 0.001), under the random-effects model
(I2 : 49.9%, PQ <0.001). From stratification analyses for ethnicity, alcohol drinking, Helicobacter pylori infection, an
effect modification of gastric cancer risk was found in the subgroups of ethnicity, smoking status, Helicobacter
pylori infection, whereas null result was found in the subgroups of alcohol drinking. We also undertook gene-gene
interaction analysis between GSTM1 and GSTT1 genes for gastric cancer risk, and the results indicated that the
dual null genotypes of GSTM1 and GSTT1 might elevate the risk of gastric cancer (OR = 1.505, 95% CI: 1.165-1.944,
P = 002).
Conclusions: This meta-analysis suggests that the null genotype of GSTM1 may be a important genetic risk factor
for gastric cancer development.
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The incidence and mortality of gastric cancer (GC) has
been substantially falling over the last few decades in most
parts of the world [1], however, gastric cancer was still the
second most common cancer worldwide (989,600 new
cancer cases) and also the second most common cause of
cancer mortality (738,000 deaths) in 2008 [2]. As a long,
complicated and multi-factorial process, gastral carci-
nogenesis is still not fully understood. Several suspected
environmental risk factors for the development of gastric
cancer are dietary habits, including high consumption of
salty food and low consumption of fresh fruits and vege-
tables, cigarette smoking, and alcohol consumption, as
well as Helicobacter pylori infection [3-5]. In addition to
these, genetic factors also play an important role in gastric
cancer aetiology, demonstrated by the fact that a large* Correspondence: junqiangchen8@163.com
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unless otherwise stated.proportion of individuals with the known environmental
risk factors never develop gastric cancer while many
gastric cancer cases develop among individuals without
these known environmental risk factors. Therefore, in-
vestigation of the responsible genetic polymorphism
which may increase host susceptibility to gastric cancer
is equally important to the identification of environ-
mental risks for a better understanding of interindivi-
dual variation in response to carcinogen exposures and
cancer susceptibility [6,7].
Glutathione-s-transferases (GSTs) are one of the most
important supergene family of phase II isoenzymes known
to catalyze the detoxification of reactive electrophilic com-
pounds, such as carcinogens, therapeutic drugs, environ-
mental toxins, and products of oxidative stress, chiefly by
conjugation with soluble glutathione [8]. In addition, GSTs
are able to modulate the induction of other enzymes and
proteins which are important in cellular functions, such as
DNA repair, and are therefore important in maintaining
genomic integrity [9]. In this respect, the GST enzymesn Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
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humans, GSTs are divided by electrophoresis into at least
four major classes, namely Alpha, Mu, Pi, Theta [10].
GSTM1 and GSTT1 are the genes that encoding the
Mu class and the Theta class of GSTs, respectively. The
GSTM1 gene is located on chromosome 1p13.3 and
contains 10 exons, and the GSTT1 gene is mapped to
chromosome 22q11.23 and contains six exons. The com-
mon variants of GSTM1 and GSTT1 genes is the homozy-
gous deletion (null genotype), which has been reported to
causes the loss of enzymic activity and might higher the
risk of various cancers. A recent meta-analysis [11] has
suggested that an increase in gastric cancer risk was asso-
ciated with GSTT1 deficiency. However, a review of gen-
etic susceptibility and gastric cancer risk reported that the
results of case–control studies detailing associations bet-
ween the GSTM1 gene and gastric cancer risk are contro-
versial [12]. Since Strange et al. firstly published the study
showing an association between GSTM1 null genotype
and a possible excess risk of developing gastric cancer in
1991 [13]. Subsequently, numerous researchers have con-
secutively reported on the same issue in various popula-
tions, but with mixed, or even conflicting results [14-65].
One of major problems with the published studies is that
many of them included relatively small sample size. Fur-
thermore, because the GSTM1 null genotype is regarded
as a potential contributor to gastric cancer risk by influen-
cing detoxification of activated environmental carcinogens
and by interaction with unfavourable GSTT1 polymor-
phism, the possible modifying effects of GSTM1 status on
the relationship between smoking status, alcohol drinking,
Helicobacter pylori infection,GSTT1 polymorphism and
gastric cancer risk is of great interest, even though not
often investigated.
To obtain more precise estimate for the association
between GSTM1 polymorphism and gastric cancer risk,
we conducted a quantitative meta-analysis of all available
studies published until August 15, 2014. In addition, we
performed subgroup analysis stratified by smoking sta-
tus, alcohol drinking and Helicobacter pylori infection to
explore the possible effects of the interactions between
GSTM1 genotype and above environmental risk factors,
and gene–gene interaction analysis between GSTM1 and
GSTT1 genotype with respect to gastric cancer risk.
Materials and methods
Data sources and search
We conducted a comprehensive database searching for
PubMed, Embase, and Cochrane Library through August
15, 2014 for relevant studies that estimated the associa-
tion between GSTM1 polymorphism and risk of gastric
cancer using the following search terms: (1) gastric cancer,
gastric carcinoma, gastric adenocarcinoma, stomach neo-
plasm, stomach cancer, GC; (2) Glutathione-s-transferases,GSTs, GST mu, GSTM, GSTM1, GST1; (3) polymorphism,
SNP, variant, mutation, genetic polymorphism. The scope
of the computerized literature search was also expanded
on the basis of the reference lists of eligible articles. There
was no restriction on language.
Eligibility criteria and study selection
We first performed an initial screening of titles or ab-
stracts to find potentially appropriate articles. A second
screening was based on full-text review to identify those
containing useful data on the topic of interest for in-
clusion in the meta-analysis. Studies were considered eli-
gible if they met the following criteria: (1) publications
assessed the relationship between GSTM1 status and
gastric cancer; (2) used a cohort or case–control studies
design; (3) had an appropriate description of GSTM1
status in cases and controls; (4) repored an odds ratio
(OR) with 95% confidence interval (CI) or other avail-
able data for calculating OR (95% CI). Furthermore,
when data from a single unique study population was
republished by the same author or written in English,
only the most recent article or largest report was consi-
dered. When a study reported the results on different
subpopulations, we treated them as separate studies in
the meta-analysis.
Data extraction
Each article was extracted by two independent resear-
chers (X Lao and Q Peng), who are blinded with respect
to the authors, institutions and journals, using a struc-
tured sheet and entering into a database. The following
data were extracted: first author, year of publication,
country, ethnicity of study populations (categorized as
Asian, Caucasian, and Negroid), number of cases and
controls, gastric cancer diagnosis method, source of con-
trol selection, matching criteria between cases and con-
trols, genotyping method, exposures of smoking, alcohol
consumption, Helicobacter pylori infection or GSTT1
genetic polymorphism in cases and controls, GSTM1
status in cases and controls. If there were any dis-
crepancy between these two investigators, a discussion
would be carried out to make an ultimate decision
through the third investigator (S Li).
Data synthesis and statistical analysis
The strength of the association between the GSTM1
polymorphism and gastric cancer risk was measured by
the odds ratio (OR) with 95% confidence interval (CI).
The significance of the pooled OR was determined by Z
test and a P value of less than 0.05 was considered sig-
nificant. Then, we examined the associations between
null genotype of GSTM1 and gasreic cancer risk on the
genetic comparison model (null genotype vs. present
genotype).
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dichotomous outcomes were conducted: the random-
effects model and the fixed-effects model. The random-
effects model, using the DerSimonian-Laird method
[66], was conducted to pool the results when hetero-
geneity between studies existed on the basis of Q-test
P-value which was less than 0.1 [67]. The fixed-effects
model, using the Mantel-Haenszel method [68], was uti-
lized to pool the results if the Q-test P value was more
than 0.1. Besides, the I2 statistic was calculated to assess
the between-study heterogeneity, and heterogeneity was
deemed as apparent when the I2 statistic value was
greater than 50%. Furthermore, several subgroup meta-
analyses were performed in an attempt to assessed the
association between the GSTM1 null genotype and gas-
tric cancer risk based on the ethnicity, smoking status,
alcohol drinking and Helicobacter pylori infection. For
these purposes, we stratified subjects (both GSTM1
present and null genotypes) according to ethnicity (cate-
gorized as Asians, Caucasians and Negroids ), smoking
status (non/ever smokers); alcohol drinking (non/ever
drinkers); Helicobacter pylori infection (negative/positive
infection). In order to evaluate the presence of a bio-
logical interaction between GSTM1 and GSTT1 poly-
morphisms, additional gene–gene interaction analysis
were performed by using the individuals with present ge-
notypes for both genes as reference groups, as suggested
by Botto and Khoury [69].
To validate the credibility of outcomes in this meta-
analysis, a sensitivity analysis was performed by sequen-
tial omission of individual studies. Publication bias was
investigated using a funnel plot, in which the standard
error of logor of each study was plotted against its logor.
An asymmetric plot suggested the existence of possible
publication bias. In addition, funnel-plot asymmetry was
formally assessed by the method of Egger’s linear regres-
sion test [70]. If publication bias existed, the Duval and
Tweedie non-parametric “trim and fill” method was used
to adjust for it [71]. All analyses were performed using
Stata software, version 12.0 (Stata Corp, College Station,
TX). All P values were two-sided. To ensure the re-
liability and the accuracy of the results, two authors
(Lao X and Peng Q) entered the data into the statistical
software programs independently with the same results.
Result
Identification of relevant studies
After comprehensive searching, a total of 202 articles were re-
trieved, but only 49 full-text publications [15-21,23-27,29-65]
which catered to the inclusion criteria were finally included
in our meta-analysis. Additonal four studies [13,14,22,28]
were identified by reviewing the bibliographies of the
retrieved articles (Figure 1). Besides, because there was
a study [29] containing two different ethnic populations(Caucasians and Negroids), we treat it as two individual
case–control studies. Thus, in our meta-analysis we ini-
tially included a total of 54 studies which assessed the
associations between GSTM1 polymorphism and gastric
cancer. The 54 studies were published from 1991 to
2013 with 35 were carried out in Asian countries, 11 in
Europe countries, and eight in America. Of these 54
studies, 51 were case–control design, while the other
three were nested case–control design from cohort. The
number of cases in the included studies for GSTM1 de-
letion varied from 5 to 1225 patients. There were 14
studies focused on the joint effect of GSTM1 null geno-
type and smoking status on gastric cancer risk, four in-
vestigated the joint effect of GSTM1 null genotype and
alcohol drinking, and seven eveluated the joint effect of
GSTM1 null genotype and Helicobacter pylori infection.
15 studies investigated the gene-gene interaction be-
tween GSTM1 and GSTT1 polymorphisms in the asso-
ciation with gastric cancer risk. Table 1 presents a brief
description of these 54 studies.
Meta-analysis results
Table 2 lists the main results of this meta-analysis.
The results of pooling all studies showed that the null
genotype of GSTM1 was associated with an increased
gastric cancer risk (OR = 1.207, 95% CI: 1.106-1.317,
P < 0.001), using the random-effects model (I2 : 49.9%,
PQ < 0.001) (Figure 2). As shown in Tables 2, specific data
were stratified, on the basis of ethnicity, into three sub-
groups: Aians, Caucasians and Negroids. Statistically sig-
nificant findings were found in Asians and Caucasians but
not in Negroids. The pooled OR were 1.264 (95% CI:
1.164-1.422, P < 0.001, P for heterogeneity = 0.002) in
Aians, 1.154 (95% CI: 1.008-1.321, P < 0.037, P for hetero-
geneity = 0.001) in Caucasians, and 1.182 (95% CI: 0.142-
9.827, P < 0.887) in Negroids, respectively.
The data were also stratified, in accordance with the
smoking status, into non-smokers and ever-smokers
subgroups. Statistically significant findings between the
null genotype of GSTM1 and gastric cancer risk was
found in both non-smokers (OR = 1.370, 95% CI: 1.043-
1.800, P < 0.024, P for heterogeneity = 0.028) and ever-
smokers subgroups (OR = 1.558, 95% CI: 1.111-2.183,
P < 0.010, P for heterogeneity < 0.001), respectively. The
data were additionally stratified, in line with alcohol
driking, into the subgroup of non-drinkers and ever-
drinkers. However, null results were noted in both non-
drinkers (OR = 0.872, 95% CI: 0.623-1.220, P = 0.425,
P for heterogeneity = 0.757) and ever-drinkers (OR = 1.112,
95% CI: 0.771-1.602, P = 0.570, P for heterogeneity =
0.905). The data were further stratified, in the light of
Helicobacter pylori infection, into Helicobacter pylori nega-
tive and Helicobacter pylori positive subgroups. Statistically
significant findings could be found only in Helicobacter
Figure 1 Flowchart of the selection of studies for inclusion in the meta-analysis.
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P < 0.013 P for heterogeneity = 0.076), but not for Helico-
bacter pylori negative subgroup (OR = 0.869, 95% CI:
0.654-1.156, P < 0.334, P for heterogeneity = 0.373).
Table 3 shows the OR and 95% CI of GSTM1 and
GSTT1 combined genotypes in gastric cancer cases and
controls from 15 studies. We designated the present
genotype individuals for both GSTM1 and GSTT1 genes
as reference groups. There was an interaction that only
observed for individuals with combined deletion mu-
tations of GSTT1 and GSTM1 genes for gastric cancer
risk (OR = 1.505, 95% CI: 1.165-1.944, P = 002). This
shows that the null genotype of GSTM1 might increase
gastric cancer risk associated with the GSTT1 null
genotype.
Sensitivity analysis and publication bias
A sensitivity analysis was performed by the sequential
omission of individual studies. The significance of the
pooled OR in both the overall analysis and subgroup
analysis were not influenced excessively by omitting any
single study (data were not shown).
Begg’s funnel plot and Egger’s test were performed to
access the publication bias of literatures. As shown in
Figure 3, the shape of the funnel plots seemed asymmet-
rical suggesting the presence of publication bias. Then,
the Egger’s test was adopted to provide statistical evi-
dence of funnel plot asymmetry. As expected, the results
have shown that publication bias was evident in this
meta-analysis (P = 0.004). Hence, the non-parametric
“trim and fill” method [71], suggested by the Duval andTweedie, was used to adjust for it. Meta-analysis with
and without “trim and fill” method did not draw differ-
ent conclusion (data not shown), indicating that our re-
sults were statistically robust.
Discussion
The present and null genotype of GSTM1 is one of the
most widely studied metabolic gene polymorphisms as
susceptibility factor for gastric cancer. In 2005, La Torre
et al. [72] firstly performed a meta-analysis about the as-
sociation between GSTM1 genetic polymorphism and
gastric cancer susceptibility, and the results suggested
that GSTM1 deficiency possiblely has no effect on gas-
tric cancer risk, but may modulate tobacco-related car-
cinogenesis of gastric cancer. Since then, additional
expanding body of literatures assessing such association
were conducted by Chen et al. [73] and Zhu et al. [74].
Both of them found that a excess gastric cancer risk was
probably associated with GSTM1 null genotype in
Asians, but not in Caucasians. Besides, Chen et al. re-
vealed that smoking, Helicobacter pylori infection status
did not modify the association between GSTM1 null
genotype and gastric cancer risk. However, these pre-
vious meta-analysis did not cover all eligible studies pub-
lished in Pubmed and even contain the overlapped data,
which made their conclusions doubtable. What’s more,
12 new case–control studies [54-65] have been pub-
lished since 2010. Hence, to derive the most comprehen-
sive assessment of the associations between the GSTM1
polymorphism and gastric cancer risk, we undertook an
updated meta-analysis of all available studies. The main
Table 1 Characteristics of included studies of gastric cancer and GSTM1 status
Study Ethnicity (region) No. of
cases/
controls








Caucasian (Britain) 19/49 Histologically
confirmed






Asian (Japan) 19/84 NA Healthy volunteers NA PCR NA 14(73.7) 40(47.6)
Shunji Kato
1996 [15]
Asian (Japan) 64/120 Histologically
confirmed
Clinic based Age,gender PCR-RFLP NA 30(46.9) 61(50.8)
Takahiko Katoh
1996 [16]
Asian (Japan) 139/126 Histologically
confirmed
Healthy volunteers Age Multiplex PCR Smoking status 79(56.8) 55(43.6)
Mark Deakin
1996 [17]
Caucasian (Britain) 136/577 NA Clinic based NA PCR NA 72(52.9) 316(54.8)
Liakhovich VV
1997 [18]
Caucasian (Russia) 49/53 NA Healthy volunteers NA PCR NA 21(42.9) 21(39.6)
Enders K. W. Ng
1998 [19]





Caucasian (Portugal) 148/84 Histologically
diagnosis















Caucasian (Poland) 347/426 NA Population based Age,gender PCR-RFLP NA 167(48.1) 222(52.1)
Lin Cai 2001 [23] Asian (China) 95/94 Histologically or
operation
diagnosis






Caucasian (Iran) 42/131 Pathologically
diagnosis




Caucasian (Italy) 8/100 NA Healthy volunteers NA PCR NA 5(62.5) 53(53.0)
Ming-Shiang Wu
2002 [26]
Asian (China) 356/278 Histologically
diagnosis
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Suck Chei Choi
2003 [28]
Asian (South Korea) 80/177 Pathologically
diagnosis


















Age,gender Multiplex PCR NA 2(15.4) 2(13.3)
Mark J. Roth
2004 [30]







Age,gender RT-PCR NA 66(73.3) 145(31.9)
Shioto Suzuki
2004 [31]




Caucasian (Costa Rica) 31/51 Pathologically
diagnosis
Healthy volunteers NA Multiplex PCR NA 15(48.4) 26(51.0)
María M. Torres
2004 [33]
Caucasia (Colombia) 46/96 Pathologically
diagnosis
Healthy volunteers Age,gender Multiplex PCR NA 30(65.2) 36(37.5)
Jing Shen 2005
[34]
Asian (China) 112/675 Endoscopic and
pathological
diagnosis
Healthy volunteers NA PCR Smoking status 71(63.4) 361(53.5)
Kuang-Chi Lai
2005 [35]
Asian (China) 123/121 Histologically or
operation
diagnosis
Healthy volunteers NA Multiplex PCR NA 73(59.3) 55(45.5)
Hao Li 2005 [36] Asian (China) 100/62 Pathologically
diagnosis






Asian (China) 196/393 Pathologically
diagnosis
Population based Age,gender PCR NA 127(64.8) 235(59.8)
Hong-Mei Nan
2005 [38]
Asian (South Korea) 400/614 Histologically
diagnosis
Clinic based Age,gender Multiplex PCR NA 251(62.8) 360(58.6)
Lulufer Tamer
2005 [39]
Caucasian (Turkey) 70/204 Histologically or
operation
diagnosis











center and date of
blood collection
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Kuen Lee
2006 [41]
Caucasian (Chile) 73/263 Histologically
diagnosis










Multiplex PCR GSTT1 genotyping 33(37.9) 149(45.3)
Su Hyung Hong
2006 [43]
Asian (South Korea) 108/238 Histologically
diagnosis








Caucasian (Italy) 107/254 Histologically
diagnosis






Caucasian (Italy) 79/112 Pathologically
diagnosis






Caucasian (America) 116/208 Histologically
diagnosis












Caucasian (Oman) 107/107 NA Healthy volunteers Geographical
origin






Caucasian (Iran) 67/134 Pathologically
diagnosis



















Age and date of
biospecimen
collection
TaqMan GSTT1 genotyping 98(57.6) 415(56.5)
Kazem Zendehdel
2009 [52]
Caucasian (Sweden) 124/469 NA Population based Age,gender Multiplex PCR Smoking status 70(56.5) 239(51.0)
Jin-Mei Piao
2009 [53]
Asian (South Korea) 2213/1699 Histologically
diagnosis
Healthy volunteers NA TaqMan GSTT1 genotyping 1225(55.4) 923(54.3)
Thai V. Nguyen
2010 [54]
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Domenico Palli
2010 [55]
Caucasian (Italy) 296/546 Histologically
diagnosis








Age,gender Multiplex PCR NA 49(37.0) 120(44.0)
Mohamad Darazy
2011 [57]
Caucasian (Lebanon) 13/70 Histologically
diagnosis
Healthy volunteers Age,gender PCR NA 6(46.2) 12(17.1)
Ya-ping Luo 2011
[58]
Asian (China) 123/129 Pathologically
diagnosis
Healthy volunteers NA PCR NA 93(75.6) 71(55.0)
An-Ping Zhang
2011 [59]
Asian (China) 194/412 Histologically
diagnosis
Healthy volunteers NA PCR-CTPP GSTT1 genotyping 105(54.1) 194(47.1)
Deepmala Yadav
2011 [60]



















Asian (China) 410/410 Histologically
diagnosis














Caucasian (Turkey) 50/57 Pathologically
diagnosis
Population based Age,gender Multiplex PCR NA 26(52.0) 25(43.9)
Sang-Yong Eom
2013 [65]
Asian (South Korea) 477/476 Histologically
diagnosis
Healthy volunteers Age,gender Multiplex PCR NA 263(55.1) 259(54.4)
GC, gastric cancer; NA: relative data not available in original studies; PCR: Polymerase chain reaction; PCR–RFLP: Polymerase chain reaction-restriction fragment length polymorphism; RT-PCR: Real-Time PCR;














Table 2 Summary of pooled odds ratios (OR) with confidence intervals (CI) of the GSTM1 polymorphism and gastric
cancer risk
Group of analysis n† GSTM1 (Null vs. Present*) M# Heterogeneity
OR (95% CI) POR I
2(%) PQ
※
Overall 54 1.207(1.106-1.317) <0.001 R 49.9 <0.001
Ethnicity
Asians 24 1.264(1.164-1.422) <0.001 R 51.8 0.002
Caucasians 29 1.154(1.008-1.321) 0.037 R 50.6 0.001
Negroids 1 1.182(0.142-9.827) 0.887 F —¶ —¶
Smoking status
Non-smokers 14 1.370(1.043-1.800) 0.024 R 46.7 0.028
Ever-smokers 14 1.558(1.111-2.183) 0.010 R 69.6 <0.001
Alcohol drinking
Non-drinkers 4 0.872(0.623-1.220) 0.425 F 0.0 0.757
Ever-drinkers 4 1.112(0.771-1.602) 0.570 F 0.0 0.905
Helicobacter pylori infection
Helicobacter pylori negative 7 0.869(0.654-1.156) 0.334 F 6.8 0.373
Helicobacter pylori positive 7 1.595(1.104-2.304) 0.013 R 49.9 0.076
†Number of studies included.
*The genetic comparison model for GSTM1–GSTT1interaction analysis is Dual null genotype vs. Non-null genotype.
# M, model of meta-analysis; R, random-effects model; F, fixed-effects model.
※ PQ: P values of Q-test for heterogeneity test.
¶Values could not be calculated out.
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9,322 cases and 15,118 controls is that individuals of
GSTM1 null genotype appear to have a significant in-
creased risk of gastric cancer.
Large ethnic differences for the frequency of homozy-
gous deletion in GSTM1 have been observed. Frequen-
cies of homozygous GSTM1 null genotype in Japanese,
Chinese, Indians (Asia), Caucasians and Africans were
48%-51%, 35%-63%, 33%-36%, 50%, 22%-35%, respec-
tively [75]. For the subgroup meta-analyses of ethnicity,
which categorized as Asians, Caucasians and Negroids,
the results showed that the GSTM1 null phenotype pre-
disposes to gastric cancer in both Asian and Caucasian
populations, but not in Negroids. For Caucasians, what
is notable that the association between GSTM1 null sta-
tus and gastric cancer risk simply reaches a slightly sta-
tistically significant level. Since the Caucasian reports in
the subgroup analysis include a mixture of populations
from very distant countries, the result must be inter-
preted with caution. For Negroids, it might seems that
the low prevalence of this viriant and the low number of
samples would make it difficult to detect an association
between GSTM1 null phenotype and gastric cancer risk
with only 13 cases and 15 controls. It may also be that
other gastric cancer risk factors, such as prevalence of
Helicobacter pylori infection, lifestyle, diet, or other
environmental risk factors for which ethnic groups vary,
may be responsible for the different associations ob-
served in this meta-analysis.In our meta-analysis, we proceeded the subgroup
meta-analysis of pooling data from the cases and the
controls on smoking status, and the suggestion of an
increase risk of gastric cancer was found in not only
non-smokers but also ever-smokers. Interestingly, both
the OR and the upper and lower limits of corresponding
95% CI in ever-smokers are much higher than non-
smokers. Smoking is an important established risk factor
for gastric cancer that accouts for about 50 % increase in
gastric cancer risk [76]. Jarebinski et al. [77], in 1992 first
reported that there is a weak association between smok-
ing and gastric cancer. Then, Ladeiras-Lopes et al. [78]
in 2008 conducted a meta-analysis including only pro-
spective studies to estimate the relationship between
smoking and gastric cancer, and concluded that smoking
is the most important behavioral risk factor for gastric
cancer, especially for male smokers. Nevertheless, the
mechanism by which tobacco smoke facilitates gastric
cancer development is not well recognised. Processed
tobacco contains over 3,000 compounds including 30 car-
cinogens. The mainstream and sidestream smoke gene-
rated when tobacco in cigarettes is burnt contains more
than 4,000 constituents including about 50 carcinogens
(e.g. benzo(a)pyrene, styrene-7,8-oxide, transstibene oxide,
epoxybutanes, ethylene oxide, halomethanes, and methyl
bromide). Many of these compounds are firstly metabo-
lized by phase I enzymes, and detoxified and converted to
inactive metabolites by the phase II enzymes including
GST family enzymes. Individuals who present inefficient
Figure 2 Forest plots for the null genotype of GSTM1 and gastric cancer risk of overall populations using a random-effects model (null
genotype vs. present genotype).
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http://www.cancerci.com/content/14/1/127phase II metabolism may accumulate more toxic interme-
diates when exposed to smoking, and thereby resulting in
increasing their risk of developing cancers. GSTM1 is one
of the major member of the GST family which are in-
volved in detoxification of smoking-related carcinogens.
Previous reports have showed that the null genotype of
GSTM1 causes the loss of enzymic activity [14]. So, wepropose a hypothesis that smokers who present the
GSTM1 null genotype are more susceptible to impairment
by tobacco smoke, due to the low catalytic efficiency.
Furthermore, we carried out the subgroup analysis on
alcohol drinking to detect the possible effect of GSTM1
deficiency on gastric cancer risk. Alcohol drinking is
supposed to be a risk factor of gastric cancer, due to the
Table 3 Combined genotype analysis of GSTM1 and GSTT1 on risk of gastric cancer
GSTM1 genotyping GSTT1 genotyping Cases (n = 5072) Control (n = 5775) OR (95% CI) POR
Present Present 1315 1762 1
Null 1024 1126 1.107(0.980-1.251) 0.102
Null Present 1461 1736 1.134(0.969-1.328) 0.117
Null 1272 1151 1.505(1.165-1.944) 0.002
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http://www.cancerci.com/content/14/1/127reactive oxygen species (ROSs). ROSs are produced du-
ring alcohol metabolism as a result of the generation of
NADH from the conversion of ethanol to acetaldehyde
by alcohol dehydrogenase, and may induce gastric mu-
cosal oxidative injury [79,80]. Despite the biological
plausibility of alcohol drinking as a modulator of gastric
cancer susceptibility, previously inconsistent results have
appeared. In 1988, an International Agency for Research
on Cancer (IARC) working group concluded that there
was no evidence support that alcohol dringking was
involved in the pathogenesis of gastric cancer [81]. In
2007, the IARC working group reassessed the carcino-
genesis of alcohol consumption and concluded that alco-
hol consumption might be associated with an increased
gastric cancer risk, but confounding by smoking and
dietary habits could not be ruled out [82]. GSTM1 can
detoxify many toxicological substrates, including etha-
nol, to become inactive products. Therefore, the effect of
the interactions between GSTM1 polymorphism and
alcohol drinking on gastric cancer risk should be noted.
Unfortunately, there was no association between GSTM1
null genotype and increased gastric cancer risk was
found in non-drinkers or ever drinkers in the meta-
analysis. However, only four studies with insufficient
statistic power concerning drinking status were inclu-
ded in the present mata-analysis, with possible biasesFigure 3 Begg’s funnel plots for publication bias of the null genotype
genotype vs. present genotype). Each point represents a separate studyexisted. Further investigations on the effect of the interac-
tions of GSTM1 null genotpe and alcohol drinking on gas-
tric cancer risk are required to address this controversy.
We also examined the association between Helicobacter
pylori infection and the risk of gastric cancer. Helicobacter
pylori is a spiral Gram-negative bacterium that colonizes
the stomach, and which has been implicated as a Class 1
human carcinogen for gastric cancer [83]. The pro-
mulgation was based on several scrupulously conducted
case–control studies in which chronic Helicobacter pylori
infection was shown to eveluate the risk of gastric cancer
from 2.8-to 6-fold [84,85]. There is now evidence that ap-
proximately 25–50% of the world’s population is infected
by the microorganism, and that up to 85 % of noncardia
gastric cancers are Helicobacter pylori related [86]. How-
ever, it remains obscure why quite a few individuals in-
fected do not develop the malignancy, even in areas with a
high prevalence of both Helicobacter pylori infection and
gastric cancer. Ng EK et al. found that GSTM1 null geno-
type was more prevalent in gastric cancer cases with
Helicobacter pylori infection than without the infection,
and the result suggested that the absence of GST-mu
function might have enhanced the susceptibility of these
patients to the carcinogenic process initiated or facilitated
by Helicobacter pylori [19]. In our meta-analysis, there
were six publications including a total of 1,007 cases andof GSTM1 and gastric cancer risk in the overall populations (null
for the indicated association.
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bacter pylori infection and GSTM1 polymorphism for the
risk of gastric cancer, and some risk excess was observed
among Helicobacter pylori infection positive individuals
compared with negative individuals by combining the data
available from these six studies. However, these results
should be interpreted with caution as the subset analysis
involved a small number of patients and controls that may
have affected the statistical analysis.
If genetic susceptibility to gastric cancer is, in part, me-
diated through metabolic gene polymorphisms, it is pos-
sible that the combinations of certain genotypes may be
more discriminating as risk factors for gastric cancer than
a single locus genotype. Because GSTM1 and GSTT1 are
involved in the detoxification of a variety of compounds,
and their substrates often overlap, it is possible that indi-
viduals with a more defective genotype of these genes can
be expected to at higher risk of cancers. A previous study
has looked at the combination between GSTM1 and
GSTT1 in gastric cancer and showed that a 95% signifi-
cant increased risk of gastric cancer appeared for indi-
viduals with combined deletion mutations in GSTT1 and
GSTM1 genes in comparison with individuals with both
homozygous wild genotypes [87]. Hence, we also investi-
gate the possible interaction between GSTT1 and GSTM1
status and gastric cancer risk in this meta-analysis. Even
though only 15 of 54 selected studies collected data on
GSTT1 status, a statistically significant increased risk for
gastric cancer was detected for individuals with combined
deletion mutations in both GSTM1 and GSTT1 genes
compared to those with wild genotypes by pooling the
data from available studies.
Several limitations of the study have to be acknowl-
edged in interpreting the results. Firstly, the sample sizes
for a majority of included studies were relatively small;
source of controls were somewhat different from each
other; the matching criteria for the cases and controls
were also not strict. Thus, robust guarantee could hardly
be made among all those eligible studies. Additionally,
only published studies were included in our meta-analysis
and a publication bias have occurred. Even though non-
parametric “trim and fill” method was used to adjust for
it and the result suggested that meta-analysis with and
without “trim and fill” method did not draw different con-
clusion, if the unpublished studies are not included an
overestimation of the GSTM1 null effect may inevitably
appear. Finally, the subgroup meta-analyses considering
interactions between GSTM1 null genotype and smoking
status, alcohol drinking and Helicobacter pylori infection,
as well as GSTT1 null genotype were performed by col-
lecting data from a minority of included studies, so selec-
tion bias may have occurred in this meta-analysis. What’s
more, more subgroup analyses performed on age, gender,
histological types, and other factors (such as vegetable andfruit intakes, salt and salted preserved food intakes) would
be better to investigate possible biases; however, we could
not perform subgroup analyses on these factors owing to
the limited available information in the primary literatur.
Conclusion
This meta-analysis suggests that the null genotype of
GSTM1 are associated with increased gastric cancer risk,
and the subgroup meta-analysis on the basis of ethnicity
showed that significant associations are found for Asians
and Caucasians, but not for Negroids. In additon, the null
genotype of GSTM1 may modulate the smoking-related
and Helicobacter pylori-related carcinogenesis of gastric
cancer, and that the combination of unfavourable GSTT1
polymorphism may result in an additional risk of gastric
cancer. Future studies with large and carefully design are
warranted to better understand such a association bet-
ween GSTM1 null genotype and gastric cancer risk.
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